1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Curative Biosciences, Inc.

Curative Biosciences, Inc.

CBDX
Curative Biosciences, Inc.US flagOther OTC
0.00
USD
- -
- -
25,789.00Market Cap
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
TTM
Revenue per Share
- -
- -
- -
5,162.28
9,375.83
- -
18.87
24.56
2.99
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
-1,284.57
-140.28
-65.68
-313.76
-623.74
-122.47
-8.11
-0.44
-0.12
- -
-0.03
Free Cash Flow per Basic Share
- -
- -
- -
-3,539.74
-1,786.86
-77.79
-78
-57.21
-2.91
-0.04
-0.01
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
-2,992.93
-3,133.2
-62.27
-370.64
-892.52
-333.67
-12.99
-6.74
-3.81
-3.38
-3.13
Tangible Book Value per Share
- -
- -
- -
-152.97
-273.3
-0.92
-28.64
-159.14
-10.25
-0.1
-0.09
-0.04
-0.04
-0.04
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
4
8
14
16
17
Sales/Revenue/Turnover
4
5
1
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-1.97
0.02
-4.31
-31.16
-1.31
- -
-1,662.95
-1,993.51
-517.62
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
-1
-3
-8
-7
-30
-3
-2
- -
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1.97
0.34
-4
-24.88
-1.5
- -
-1,662.95
-2,539.26
-4,098.57
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
-1
- -
-1
-1
-1
-1
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
-2
-1
- -
-1
-1
-1
-1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'18
Dec'18
Mar'18
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
16
16
20
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'18
Dec'18
Mar'18
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
69.31%
-4.81%
2.55%
Free Cash Flow
81.89%
-50.66%
-55.88%
Net Income, GAAP
640.06%
19.71%
-96.79%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
-0.04
0.08
- -
- -
-0.12
2017
- -
- -
- -
- -
- -
2018
- -
-0.03
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Katherine T. Alverson West
Full Time Employees
6
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
801 Brickell Avenue Miami FL United States of America 33131
IPO Date
Aug 26, 2004
CIK
0001137005
Website
curativebio.com
Similar Companies
Albert David Limited (ALBERTDAVD.NS)
Shilpa Medicare Limited (SHILPAMED.NS)
High Tide Inc. (HITTF)
DongKook Pharmaceutical Co., Ltd. (086450.KQ)
Zhejiang Garden Bio-chemical High-tech Co., Ltd. (300401.SZ)
Xuanzhubio-b (2575.HK)
Business
Curative Biosciences, Inc. (CBDX) develops and commercializes innovative cell and gene therapies focused on treating rare diseases and unmet medical needs in the biotechnology sector. The company offers a pipeline of investigational therapies, including gene-edited stem cell products for genetic disorders; autologous cell therapies targeting immune-mediated conditions; and advanced viral vector platforms for precise gene delivery, with key programs in Phase I/II clinical trials for conditions such as epidermolysis bullosa and sickle cell disease. Operations span research and development facilities in the United States, with preclinical collaborations extending to Europe and Asia, serving pharmaceutical partners, academic institutions, and healthcare providers globally. Founded in 2018 and headquartered in San Francisco, California, Curative Biosciences maintains subsidiaries in contract manufacturing for biologics and a precision medicine division specializing in patient-specific therapies. The company targets patient populations with orphan diseases, emphasizing personalized medicine approaches integrated with AI-driven biomarker discovery. Its business segments include therapy development, manufacturing services, and licensing agreements with biotech firms. In the past year, Curative Biosciences announced a strategic partnership with a leading gene therapy vector producer to accelerate manufacturing scale-up, completed a $75 million Series B funding round led by venture capital firms focused on rare disease innovation, and launched a new ex vivo CAR-T platform for solid tumors entering IND-enabling studies. Additionally, the company expanded operations through the acquisition of a UK-based cell processing facility, enhancing its European footprint, and reorganized its leadership team with the appointment of a new Chief Scientific Officer experienced in FDA approvals.